We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
AbbVie (ABBV - Free Report) closed at $104.21 in the latest trading session, marking a +1.38% move from the prior day. This move outpaced the S&P 500's daily gain of 0.98%. At the same time, the Dow added 0.99%, and the tech-heavy Nasdaq gained 0.5%.
Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. This is expected to be February 3, 2021. In that report, analysts expect ABBV to post earnings of $2.86 per share. This would mark year-over-year growth of 29.41%. Meanwhile, our latest consensus estimate is calling for revenue of $13.74 billion, up 57.9% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for ABBV. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% lower. ABBV is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that ABBV has a Forward P/E ratio of 8.95 right now. For comparison, its industry has an average Forward P/E of 13.96, which means ABBV is trading at a discount to the group.
Investors should also note that ABBV has a PEG ratio of 1.52 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.08 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 196, putting it in the bottom 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
AbbVie (ABBV - Free Report) closed at $104.21 in the latest trading session, marking a +1.38% move from the prior day. This move outpaced the S&P 500's daily gain of 0.98%. At the same time, the Dow added 0.99%, and the tech-heavy Nasdaq gained 0.5%.
Wall Street will be looking for positivity from ABBV as it approaches its next earnings report date. This is expected to be February 3, 2021. In that report, analysts expect ABBV to post earnings of $2.86 per share. This would mark year-over-year growth of 29.41%. Meanwhile, our latest consensus estimate is calling for revenue of $13.74 billion, up 57.9% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for ABBV. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.01% lower. ABBV is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that ABBV has a Forward P/E ratio of 8.95 right now. For comparison, its industry has an average Forward P/E of 13.96, which means ABBV is trading at a discount to the group.
Investors should also note that ABBV has a PEG ratio of 1.52 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.08 at yesterday's closing price.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 196, putting it in the bottom 24% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ABBV in the coming trading sessions, be sure to utilize Zacks.com.